Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,443 across all filing types
Latest filing 2017-01-30 Share Issue/Capital Cha…
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Appendix 3B - Exercise of Options 12 pages 285.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, application for quotation of additional securities, and related agreements. It includes detailed information about the class and number of securities issued, issue price, shareholder approvals, and compliance with ASX rules. The document is a regulatory form used by Australian companies to notify the stock exchange about new share issues and related capital changes. It does not contain financial statements or performance data, nor is it a report or presentation. It is clearly an announcement about capital changes, specifically new share issues and securities quotation. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length is substantial (15,000 characters), indicating it is the full announcement, not just a brief notice or report publication announcement.
2017-01-30 English
Appendix 4C - quarterly 5 pages 281.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed quarterly financial data including cash flows from operating, investing, and financing activities, as well as reconciliation of cash and cash equivalents. It covers a specific quarter ended 31 December 2016 and includes compliance statements referencing accounting standards. The length is over 9,000 characters and the content is substantive financial data for a quarter, not just an announcement or certification. This matches the definition of an Interim / Quarterly Report (IR). Q2 2016
2017-01-26 English
Investor Presentation 38 pages 12.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Imugene Limited's cancer immunotherapy drug development, including scientific background, clinical trial phases, market opportunities, and strategic positioning. It contains no financial statements, regulatory audit information, or formal report filings. The content is structured as a corporate presentation aimed at investors or stakeholders, focusing on the company's pipeline, technology, and clinical progress. There is no indication that this is an official annual or interim report, audit report, or earnings release. The length (15,000 characters) and detailed content support it being a full investor presentation rather than a brief announcement or regulatory filing. Therefore, the document best fits the category of Investor Presentation (IP).
2017-01-08 English
Investor Newsletter 4 pages 10.6MB
Capital/Financing Update Classification · 90% confidence The document is an investor newsletter providing a quarterly update on company activities, including management changes (appointment of CEO), recent capital raising, clinical trial progress, patent filings, and general company news. It is not a formal financial report, earnings release, or regulatory filing. The content is narrative and informative, aimed at investors but does not contain detailed financial statements or formal disclosures. It is a periodic update but not a comprehensive interim or annual report. The focus on capital raising and company developments suggests it is a capital/financing update rather than a full financial report or earnings release. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2016-12-19 English
Imugene progresses mimotope platform 2 pages 242.6KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the filing of new patent applications by Imugene Limited. It discusses intellectual property developments and patent details but does not contain financial data, regulatory filings, or meeting materials. The document length is 3771 characters, which is relatively short and focused on a specific corporate update about patents. It is not an annual report, earnings release, management report, or any other financial or governance filing. It is also not a regulatory filing or report publication announcement since it is a standalone announcement about patent filings. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2016-12-18 English
Response to ASX Aware Query 8 pages 212.0KB
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Imugene Limited to the ASX Compliance regarding an 'aware query' about a recent announcement and trading activity. It discusses compliance with ASX Listing Rules, specifically Listing Rule 3.1 about continuous disclosure of material information. The letter references prior announcements, presentations, and share price movements, and confirms that the company has complied with disclosure obligations. The content is regulatory in nature, addressing a price query and clarifying the company's position on material information disclosure. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a report itself but a regulatory response to a compliance query from the stock exchange. Therefore, the document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2016-12-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.